EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS

Muhammed Favas Kt, Maneesh Semwal, Beema T Yoosuf, Deepesh Lad, Dipika Bansal

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05676-1 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Annals of Hematology, 2024. Verfasst von Muhammed Favas Kt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar (Mohali), Punjab, India. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Concerns persist about venetoclax's long-term safety in larger populations, with limited evidence of infrequent and delayed adverse events (AEs). The study integrated safety data on venetoclax in leukemia patients from randomized controlled trials (RCTs) and FDA adverse event monitoring system (FAERS). We systematically reviewed RCTs reporting safety outcomes of venetoclax in adult leukemia patients of any gender, either monotherapy or in combination, applying advanced search on databases like PubMed, EMBASE, and ClinicalTrial.gov. The quality assessment was done using the Cochrane Risk of Bias Tool. We utilized a random effect meta-analysis to calculate risk ratio (RR) with 95% confidence intervals (CI). The Open Vigil 2.1 MedDRAv24 was used to search the FAERS database, with data available until September 2023. The disproportionality was calculated using the proportional reporting ratio and the reporting odds ratio. The study protocol for meta-analysis was registered with PROSPERO; CRD42022378006. For the safety meta-analysis, seven RCTs with available AEs were examined. A total of 942 AEs were found associated with the venetoclax group; 79% of them were in grade three or above. Venetoclax significantly increased the risk of neutropenia grade three or above (RR = 1.34, 95% CI: 1.10-1.64, p: 0.0033) compared with the control group. In FAERS, 26,436 patients were reported with AEs associated with venetoclax. Significant signal scores were observed in hematological, cardiac, vascular, and gastrointestinal disorders. 11 out of 30 generated signals, failed to meet the signal criteria upon refinement. The current study updated and improved the safety profile of venetoclax in the post-marketing period, assisting in risk evaluation and mitigation for the best possible patient health care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesRandomized Controlled Trials as TopicHumansRetrospective StudiesAdverse Drug Reaction Reporting SystemsMaleLeukemiaFemaleAntineoplastic AgentsUnited StatesUnited States Food and Drug Administration

Stichwörter der Autor:innen

Adverse eventsLeukemiaPharmacovigilanceSafetyVenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar (Mohali), Punjab, India.
  • Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar (Mohali), Punjab, India. dipikabansal079@gmail.com.

Zitieren

APA

Kt, M. F., Semwal, M., Yoosuf, B. T., Lad, D., & Bansal, D. (2024). Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS. Annals of Hematology. https://doi.org/10.1007/s00277-024-05676-1

Vancouver

Kt MF, Semwal M, Yoosuf BT, Lad D, Bansal D. Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS. Annals of Hematology. 2024. doi:10.1007/s00277-024-05676-1

BibTeX
@article{Kt2024,
  author = {Kt, Muhammed Favas and Semwal, Maneesh and Yoosuf, Beema T and Lad, Deepesh and Bansal, Dipika},
  title = {Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05676-1}
}
Kostenlos starten →